GenSight Biologics S.A. announced a private placement of common shares at a price of ?0.025 for the gross proceeds of ?1,546,199.455 on May 7, 2024.
Market Closed -
Other stock markets
|
After market 03:59:59 pm | |||
0.37 EUR | -2.25% | 0.375 | +1.35% |
Jun. 03 | Gensight Biologics S.A. Appoints William Monteith to Its Board of Directors | CI |
Jun. 03 | Gensight Biologics S.A. Appoints Ivan Tortet as Chief Financial Officer | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-19.57% | 41.82M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-13.31% | 16.5B | |
+2.44% | 13.39B | |
+27.89% | 11.1B |
- Stock Market
- Equities
- SIGHT Stock
- News GenSight Biologics S.A.
- GenSight Biologics S.A. announced that it expects to receive ?1.546199 million in funding